Figure 4.

Proportion of patients receiving COPD inhaled therapies (N=838). ^†, patients receiving SABA (n=7), SAMA + SABA (n=2), and SAMA (n=1) are grouped with “Other” (n=12) in the above figure due to small patient numbers in these categories. The types of medication included in the “Other” category (n=12) were not captured. COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β₂-agonist; SAMA, short-acting muscarinic antagonist.